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Abstract
Aim: Apply a recently developed expert elicitation procedure to evaluate the state of the current knowledge of
the two brominated flame retardants (BFRs) most commonly used today; decabromo-diphenyl ether (decaBDE) and
hexabromocyclododecane (HBCD) and their potential impact on human health in order to support policy
considerations. This expert elicitation was organized by the HENVINET (Health and Environment Network)
Consortium.
Method: The HENVINET expert elicitation procedure that was used in the evaluations of decaBDE and HBCD is a
rapid assessment tool aimed at highlighting areas of agreement and areas of disagreement on knowledge-related
key issues for environment and health policy decision making.
Results: The outcome of the expert consultation on BFRs was concrete expert advice for policy makers with
specific priorities for further action made clear for both stakeholders and policy makers. The experts were not in
agreement whether or not the knowledge currently available on decaBDE or HBCD is sufficient to justify policy
actions, but most experts considered that enough data already exists to support a ban or restriction on the use of
these compounds. All experts agreed on the necessity of more research on the compounds. Priority issues for
further research were, among others:
￿ more studies on the extent of human exposure to the compounds.
￿ more studies on the fate and concentration in the human body of the compounds.
Introduction and aims
HENVINET (Health and Environment Network, http://
www.henvinet.eu) was funded by the EU under the 6th
Framework Programme, to support the development of
integrated health and environmental policies. The aim of
the HENVINET consortium was to establish a long-term
environment and health network between researchers,
stakeholders and policy makers and to make the latest
scientific opinions available for society. To achieve these
aims the HENVINET consortium was reviewing and dis-
seminating knowledge on environmental health related
issues, and the scientific knowledge was processed and
interpreted focussing on relevance for policy makers and
stakeholders. The HENVINET consortium focussed on
four priority health end points as defined in the European
Health Action Plan (EHAP); asthma and allergies, cancer,
neurodevelopmental disorders and endocrine disruptors.
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disruptive effects chosen for evaluation were the major
brominated flame retardants (BFRs) in use today; deca
brominated diphenyl ether (decaBDE) and hexabromo-
cyclododecane (HBCD). These two chemicals were
recently introduced in large quantities in man-made
products, and pros and cons for using the chemicals
have been heavily debated ever since [1,2]. HENVINET
developed an expert elicitation procedure and used it to
assess the health and policy implications for several
other environmental health issues, including phthalates,
another group of chemicals causing endocrine disruptive
effects [3]. The method and the experiences from the
phthalate evaluation were used to evaluate the health
and policy implications of decaBDE and HBCD.
The expert elicitation procedure has been much ques-
tioned, but until now it is still considered a valuable com-
plement to science for supporting policy making before
sufficient scientific data is available, as it helps highlight
areas of uncertainties in the discussed topic [4,5]. Experi-
ences from the HENVINET phthalate project showed that
the initial review on phthalates by the project members
did not succeed in bringing forward the most important
messages to policy makers [6]. For this reason, an expert
elicitation procedure was decided upon as a possible tool
to reach the policy makers, similar to what was presented
in Krayer von Krauss et al., 2008 [7]. An extensive review
of the consultation of experts in all four priority areas of
the HENVINET consortium, with an overall discussion
and analysis of the outcome, was recently made by Keune
et al., [8].
We here report the results of the expert elicitations on
decBDE and HBCD that were conducted during the
spring of 2009. The goal of the elicitations was to identify
the most relevant knowledge gaps, the degree of agree-
ment and disagreement on aspects of the assessment of
human health effects from these two substances. When
relevant, concrete advice for policy makers was included.
Background
DecaBDE and HBCD are the two major BFRs used to
prevent building materials, electronics, clothes and furni-
ture from catching fire [1,9]. The major concerns about
decaBDE and HBCD are their persistence in the environ-
ment, their potential for bioaccumulation, and indica-
tions of toxicological effects.
DecaBDE
DecaBDE differs from other brominated diphenyl ethers
(BDEs) with respect to some important physicochemical
properties making it less bioaccumulative and less toxic.
In many countries decaBDE has therefore been less strictly
regulated than the other BDEs. Even if regarded as less
toxic, there are indications of toxicological effects, such as
endocrine and neurodevelopmental disturbances [10]. In
2008 decaBDE was therefore banned from being used in
electrical and electronic products in the EU [11]. Finally in
August 2010 decaBDE was registered under the EU’s
REACH Regulation [2]. In Norway decaBDE was totally
banned already in 2008 [2]. The states of Maine, Washing-
ton, Vermont and Oregon have restricted the use of dec-
aBDE in certain products, but still many major uses of the
substance are allowed in North-America [2]. On Decem-
ber 17, 2009, as result of negotiations with the EPA, the
two U.S. producers of decaBDE and the largest U.S.
importer of decaBDE announced commitments to phase
out decaBDE in the United States. Production, import,
and sales of decaBDE for most uses in the United States
must end by December 31, 2012, and all uses of decaBDE
must end by the end of 2013 [12]. The use of Deca-BDE is
not subject to any regulatory restrictions in Asia [2].
HBCD
Concentrations of HBCD in the environment have
increased since 2001 [13], probably caused by the
increased use of HBCD when replacing other banned or
withdrawn BFRs (e.g. Penta BDE and OctaBDE). Indica-
tions of toxicological effects are reported for HBCD, such
as endocrine disruption effects [9]. Different countries use
different policies regarding the production and use of
HBCD, but there are hardly any restrictions on the pro-
duction or use of HBCD today: Canada, Australia and
Japan have different national assessments of HBCD under
preparation, Ukraine has registered HBCD on their hazard
chemical list, and Norway included HBCD in its national
action plan for BFRs in 2007 [14]. On June 2
nd 2009 the
European Chemicals Agency (ECHA) within the REACH
framework decided to restrict the use of HBCD within the
EU such that it can only be used when “authorized” for
specific purposes [15]. Only very recently, on August 18
th
2010 the U.S. Environmental Protection Agency (EPA)
included HBCD in the EPA’s List of Chemicals of Con-
cern, and they plan to finalise a review of HBCD in 2012
[16,17]. HBCD is currently being reviewed for global
agreement of restriction by the Stockholm Convention on
Persistent Organic Pollutants [18], and decisions in Octo-
ber 2010 concluded that HBCD should now proceed to
the risk management phase, and that a global phase-out
can be taken up for consideration in 2013 [14].
Alternative substances to decaBDE and HBCD with
putatively lower risks have been proposed [19,20], but
knowledge on the potential risks of these compounds
are limited and further investigation is required.
Methodology
Detailed description of the work flow in the expert elici-
tation procedure that we used to assess the health and
policy implications of decaBDE and HBCD can be found
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the review by Keune et al., [8].
Prior to the expert consultation, certain preparations
were necessary: First, we wrote a short background docu-
ment based on existing reviews and recent publications
from 2007-2009, then, a cause-effect diagram was devel-
oped to illustrate the scientists’ current understanding of
the cause-effect relationship between the production and
use of decaBDE and HBCD and their potential impact on
health (Figure 1), and finally, an online questionnaire-
tool was made [3]. The background documents together
with the questionnaires can be found at http://henvinet.
nilu.no/EvaluationofKnowledge/tabid/1333/language/en-
US/Default.aspx. Login required. The questionnaires are
also provided in the additional files 1 and 2.
Thirty-four experts from around the world working in
the field of BFRs were asked to fill in the online question-
naire and express their confidence in the current knowl-
edge on the different aspects of decaBDE and HBCD
illustrated in the cause-effect diagram. The aim was to
identify knowledge gaps and potential areas of agreement
or disagreement regarding these issues. The experts were
selected based on their publications in the field of dec-
aBDE or HBCD in the last decade. We invited both junior
and senior scientists of both genders from around the
world. The questionnaire was divided in two parts. In Part
A the experts were asked to evaluate the cause-effect dia-
gram. In Part B the questions were connected to all the
different elements and sub-elements of the diagram. The
experts were asked to tick the box representing their con-
fidence level in the specific topic that the question con-
cerned (Very High = VH, High = H, Medium = M, Low =
L, Very Low = VL).
Finally, from these experts a group of eight was asked
to fill in a second questionnaire (se additional files 3
and 4) and to attend an expert panel workshop. Selec-
tion of the experts was done as in the phthalate study
[3], where expertise in at least one of the main topics of
the cause-effect diagram (Figure 1) was required. The
goal of the second questionnaire was to identify priori-
ties for further action and to discuss the implications of
the results of the first questionnaire for policy and
research. The experts were asked to pinpoint priority
elements in the cause-effect diagram. Based on the
results of both questionnaires, the expert panel work-
shop identified further action to be taken, such as politi-
cal decision or further research. The final aim was to
arrive at concrete policy advice for policy makers. The
expert elicitation procedure was also discussed and
judged by the experts.
As a final step, policy briefs were prepared on the cur-
rent gaps of knowledge and expert opinion of decaBDE
and HBCD and the results of this HENVINET expert
e l i c i t a t i o no nd e c a B D Ea n dH B C D( “HENVINET policy
brief on decaBDE” and “HENVINET policy brief on
HBCD” https://henvinet.nilu.no, also provided in the
additional files 5 and 6).
Results and discussion
The results from expert evaluation of the first question-
naire are provided in the additional file 7. Selected parts
of the results from questionnaire 1 are discussed below
and presented in Figure 2 &3 and in Table 1 & 2.
Results from questionnaire 2 are presented in Table 3.
Questionnaire 1 (Q1)
Twenty-three and eighteen experts responded to decaBDE
Q1 and the HBCD Q1 respectively. Fewer responses for
HBCD are due to technical problems - some of the
answers were lost.
DecaBDE
Part A - Evaluation by the experts of the cause-effect dia-
gram (Figure 1), pointed out four issues. 1) The diagram
lacks the effects caused by the degradation products of
decaBDE. This should be in focus, as environmental
degradation of decaBDE results in lower brominated BDEs
that are known to be toxic [21-23]. 2) The last box in the
diagram (“Social, cultural, political, economical and judi-
cial settings”)w a st h o u g h tt ob eu n c l e a r .3 )I m p o r t a n t
health effects including cancer, reproduction, and multiple
organ should be added to the toxicology part, and biota,
biosphere, and food stuff should be added to the environ-
mental matrix part. 4) Food processing should be a sepa-
rate element, since there is a suspicion that food is
contaminated by decaBDE while processed. We updated
the diagram to fit the suggestions from the experts.
Part B - Evaluation of the individual parameters of the
cause-effect diagram. The results are illustrated in
Figure 2 and Table 1.
There was very high confidence in knowledge of certain
areas of exposure and environmental matrix: the level of
exposure of occupationally exposed, the main sources of
exposure of occupationally exposed, the occupational
exposure through inhalation, the exposure of infants
and children via breast milk, and the concentrations of
decaBDE in environmental matrix of sediments, sewage
sludge, and soil. Data on these topics have been thor-
oughly reviewed by Frederiksen et al., [24] and Law
et al., [13] and confirm the good confidence level.
Experts expressed very low confidence in knowledge in
certain toxicity issues such as human epidemiological
studies and the mechanisms of actions of metabolites of
BDE209,, because there is insufficient data. This was
also concluded by the US EPA [10]. Some studies on
the mechanisms of action show interaction of decaBDE
with the cholinergic system and with the steroid hor-
mone homeostasis [25,26], but the metabolites of
BDE209 have not been specifically studied.
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largely related to the lack of knowledge about the final
metabolite concentration in target tissues. Relatively
high concentrations of decaBDE have been measured in
blood and liver [10], but the final metabolite concentra-
tion in the target tissue is not easy to quantify. This
Figure 1 Cause-effect diagram of decaBDE and HBCD. The diagram illustrates the scientists current understanding of the cause-relationship
between the production and use of decaBDE and HBCD and their potential impact on health, based on existing reviews and recent
publications from 2007-2009.
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explained by: 1) in vivo debromination of decaBDE to
toxic lower BDEs [10,27], or by; 2) differences in absorp-
tion and excretion of decaBDE compared to other lower
brominated diphenyl ethers [28].
The experts disagreed most in areas where only a
handful of scientific studies exist. These topics were: 1)
neurodevelopment toxicity in females and males
exposed during foetal or neonatal life, an issue much
debated recently[8,10,29]. BDEs have been reported to
interfere with the thyroxin level that can play a crucial
role in brain development, and recently real-life scenario
studies of neurodevelopment in animals with lower
dosages of decaBDE were done that showed neurobeha-
vioural effects [28,30]2) reproductive function toxicity in
females and males exposed during foetal or neonatal
life, 3) toxicokinetics concerning to what extent BDE
209 is excreted via urine, and 4) the environmental
matrix issue of the concentration of decaBDE in water.
HBCD
Part A - Evaluation of the cause-effect diagram (Figure 1).
Two issues in need of specific focus were identified. 1)
The analytical techniques GC/MS and LC/MS for
measuring concentrations of HBCD differ and the results
cannot be compared [13,31]. 2) The differences in beha-
viour of each HBCD diastereoisomer need more focus.
Recent studies on animals show that isomers of HBCD are
selectively metabolised and enriched in the body [9].
The experts further suggested that more health-effect
endpoints were included in the toxicology part, as well
as food and biota in the environmental matrix part. We
updated the diagram to fit the suggestions.
Part B - Evaluation of the individual parameters of the
cause-effect diagram. The results (Figure 3 and Table 2)
reflect the outcome of scientific studies that are available
in literature. For example, the low confidence in knowledge
and high agreement among experts is related to the lack of
knowledge of the mechanism of action of a-HBCD, b-
HBCD, g-HBCD, and other potential metabolites of
HBCD. There are reports on toxic effects on the liver sys-
tem and the thyroid system by HBCD [32-34], but there is
very little knowledge on differences between the diaster-
eoisomers, as the technical mixture contains all three. The
high agreement on medium confidence of knowledge in
the toxicokinetics issues corresponds with the published
data as reviewed by the European Commission [9].
Figure 2 Consensus scores and average confidence scores for each question from the first decaBDE questionnaire. The average
confidence scores are calculated assigning the answer categories ordinal values (VH=5, H=4, M=3, L=2, VL=1). The question belonging to the
same diagram element box are indicated by the same symbol. EM=Environmental Matrix, EX=Exposure, SO=Source, TK=Toxicokinetics,
TX=Toxicity).
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agreements that did not match the findings in recently
published literature. In particular, the experts highly dis-
agreed in our confidence of knowledge in toxicity of the
nervous system in males and females exposed as adults.
Some studies exist on the topic, indicating developmental
neurotoxic effects in rats [35] and humans [36] and also
neurotransmitter effects on cell systems [37-39]. There is a
clear disagreement among the expert scientists whether
this data is sufficient knowledge or not. Furthermore,
there was high disagreement in our confidence in knowl-
edge in some topics of exposure: occupational exposure,
and exposure of infants and children via food and inhala-
tion, even though no real studies exist. There are only
some estimated data available on these exposure issues,
reviewed by the European Commission [9], so it is uncer-
tain why some experts consider us to have high confidence
in knowledge on these topics.
Questionnaire 2 (Q2) and the expert panel workshop
Priority areas for DecaBDE
The top three areas to study further in order to assess the
health risk of decaBDE were identified (Table 3a). First,
better understanding of the magnitude of environmental
transformation of decaBDE is needed, as the extent of
degradation of decaBDE is not fully characterized. This is
in agreement with a recent review [23] and with the evi-
dence of transformational processes involving microor-
ganisms or sunlight resulting in more bioavailable and
toxic BDEs [21] ,[22]. Second, better data on the extent of
oral exposure in humans, fr o mf o o da n dd u s ti sn e e d e d ,
consistent with. Frederiksen et al., [24]. Third,t h ef a t eo f
decaBDE in is not known. The experts questioned
whether and to what degree decaBDE is metabolised in
the human body to other more accumulating and toxic
lower brominated BDEs such as pentadiphenyl ether, or
readily excreted with or without metabolism. In addition,
more knowledge on toxicological health effects was also
highly prioritized.
Priority areas for HBCD
There was a general opinion that at present there is insuf-
ficient data available to allow health impact assessment of
HBCD. The top issues (Table 3b) were largerly in agree-
ment with the recent review [9]. First, epidemiological and
toxicological studies in humans are needed as the data
from toxicological studies of the targets of HBCD and of
the mechanism of action of HBCD are limited. This is
confirmed by a recent review [9] showing that all results
Figure 3 Consensus scores and average confidence scores for each question from the first HBCD questionnaire The average confidence
scores were calculated assigning the answer categories ordinal values (VH=5, H=4, M=3, L=2, VL=1). The question belonging to the same
diagram element box are indicated by the same symbol. EM=Environmental Matrix, EX=Exposure, SO=Source, TK=Toxicokinetics, TX=Toxicity).
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cal study on the effects of prenatal exposure of healthy
infants to HBCD [36] shows some negative effects on
sexual and psychomotor development. Second, measure-
ments of HBCD concentrations in the target tissues are
needed, due to lack of adequate studies and because of
Table 1 Selected questions on decaBDE that scored high or low (outside the 10-90 percentile range) in the average
confidence score (Mean) (a) or in consensus (CNS) (b).
(a)
Deca Questions VH H M L VL No. Resp. Mean Std CNS RANK (CONS)
54321
Environmental Matrix
EM3 Sediments 2 13 5 3 0 23 3.61 0.69 0.71 25
EM4 Sewage sludge 2 12 7 2 0 23 3.61 0.84 0.73 20
EM5 Soil 3 9740 2 3 3.48 0.78 0.66 39
Level of exposure
EX2 Occupationally exposed 1 12 8 2 0 23 3.52 0.73 0.75 15
Main sources of exposure
EX5 Occupationally exposed 3 13 6 1 0 23 3.78 0.74 0.77 12
Occupational exposed
EX11 Inhalation 4 8 10 1 0 23 3.65 0.83 0.71 27
Infants and children
EX17 Via breast milk 2 14 4 2 1 23 3.61 0.94 0.68 34
Toxicokinetics
TK10 Final metabolite concentration in target tissues 0 1 3 10 9 23 1.83 0.83 0.73 22
Human Epidemiological studies
TX01 Males 0 1579 2 2 1.91 0.92 0.68 33
TX02 Females 0 1 4 7 10 22 1.82 0.91 0.69 32
Knowledge of the mechanisms of actions
TX16 Metabolites of BDE209 0 2 1 14 5 22 2.00 0.82 0.80 4
(b)
Deca Questions VH H M L VL No.Resp. Mean Std CNS RANK (CONS)
54321
Environmental Matrix
EM6 Water 2 4863 2 3 2.83 0.95 0.59 57
Level of exposure
EX1 The general population 0 2 15 6 0 23 2.83 0.58 0.83 2
General population
EX9 Ingestion 1 4 14 4 0 23 3.09 0.73 0.80 5
Occupational exposed
EX10 Direct contact dermal 0 3 15 5 0 23 2.91 0.60 0.84 1
Toxicokinetics
TK04 Debrominated or metabolized by the intestinal microflora 0 0 7 15 1 23 2.26 0.54 0.82 3
TK07 Excreted via urine 2 5583 2 3 2.78 1.20 0.55 58
Neurodevelopment
TX05 Males exposed during fetal or neonatal life 2 2873 2 2 2.68 1.13 0.60 55
TX06 Females exposed during fetal or neonatal life 2 1964 2 2 2.59 1.14 0.59 56
Reproductive function in
TX13 Males exposed during foetal or neonatal life 1 3774 2 2 2.55 1.10 0.60 53
TX14 Females exposed during foetal or neonatal life 1 3774 2 2 2.55 1.10 0.60 54
Knowledge of the mechanisms of actions
TX16 Metabolites of BDE209 0 2 1 14 5 22 2.00 0.82 0.80 4
The questions were “What is your level of confidence in the quality of the current scientific data on…” or “What is your level of confidence in the scientists’
ability to predict…” followed by the text in the left side of the table. VH, H, M, L, VL = levels of confidence; No. Resp. = number of respondents; Std = standard
deviation; Mean = arithmetic mean of confidence score; CNS = consensus score (agreement); RANK (CNS) = consensus rank.
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mers. Third, studies of human exposure to HBCD was
prioritized, since the experts considered that too little is
known about normal exposure routes to the general popu-
lation and that knowledge on exposure is essential in a risk
assessment. This is in agreement with the few available
studies , such as the indications of transfer of HBCD to
cord blood and mother’s milk in humans [40-43] and the
estimations of exposure of different population groups [9].
Further action for decaBDE and HBCD
Experts disagreed whether today’sk n o w l e d g eo nt h e
risks of decaBDE and HBCD justifies a more drastic pol-
icy intervention. Most experts suggested to use the pre-
cautionary principle andintroduce regulations restricting
and prohibiting activities. A minority of experts felt that
more data and better understanding are required before
drastic policy measures can be justified.The arguments
for policy actions were:
￿ Large build-up in the environment was shown for
HBCD [44] and for decaBDE [22,28].
￿ It is unethical to pollute a whole population with a
chemical with unknown toxicological properties just to
prevent a few deaths caused by fire.
￿ DecaBDE is persistent and transforms into bioaccu-
mulating and toxic compounds [10,22,23]. The HBCD is
persistent and bioaccumulates [9].
￿ Concentrations of decaBDE were detected in remote
areas with no use or production of these compounds,
Table 2 Selected questions on HBCD that scored high or low (outside the 10-90 percentile range) in the average
confidence score (Mean) (a) or in consensus (CNS) (b).
a)
HBCD Questions VH H M L VL No. Resp. Mean Std CNS RANK (CONS)
54321
Environmental Matrix
EM03 Sediments 2 5 5 1 0 13 3.62 0.87 0.70 30
EM04 Sewage sludge 2 6 2 3 0 13 3.54 1.05 0.62 53
Main sources of exposure
EX05 Occupationally exposed 4 2 6 1 0 13 3.69 1.03 0.62 57
Knowledge of the mechanisms of actions
TX18 a- HBCD 0 2 1 10 5 18 2.00 0.91 0.75 10
TX19 b-HBCD 0 1 1 9 7 18 1.78 0.81 0.74 12
TX20 g-HBCD 0 1 2 10 5 18 1.94 0.80 0.77 5
TX21 Other metabolites of HBCD 0 0 1 7 10 18 1.50 0.62 0.78 3
(b)
HBCD Questions VH H M L VL No. Resp. Mean Std CNS RANK (CONS)
54321
Environmental Matrix
EM01 Debromination & biological halflives 0 3 9 1 0 13 3.15 0.55 0.84 1
Occupational exposed
EX11 Inhalation 3 2 5 3 0 13 3.38 1.12 0.59 63
EX12 Ingestion 1 3 4 4 1 13 2.92 1.12 0.62 58
Infants and children
EX14 Inhalation 1 1 4 5 2 13 2.54 1.13 0.60 61
EX16 Via food 0 3 5 2 3 13 2.62 1.12 0.59 62
Toxicokinetics
TK05 Accumulating in the body 0 6 9 3 0 18 3.17 0.71 0.77 4
TK06 Excreted via bile and faeces 0 5 8 5 0 18 3.00 0.77 0.77 6
TK08 Distribution to different tissues 0 5 12 1 0 18 3.22 0.55 0.83 2
Human Epidemiological studies
Nervous system
TX05 Males exposed as adults 1 2 3 9 3 18 2.39 1.09 0.62 59
TX06 Females exposed as adults 1 2 3 9 3 18 2.39 1.09 0.62 60
The questions were “What is your level of confidence in the quality of the current scientific data on…” or “What is your level of confidence in the scientists’
ability to predict…” followed by the text in the left side of the table. VH, H, M, L, VL = levels of confidence; No. Resp. = number of respondents; Std = standard
deviation; Mean = arithmetic mean of confidence score; CNS = consensus score (agreement); RANK (CNS) = consensus rank.
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concentrations were predicted for HBCD [46], confirm-
ing that these compounds pose a global problem.
￿ Comparison with analogous compounds where more
knowledge is available, such as polychlorinated biphenyls
(PCBs), suggests additional risks. For PCBs, risk was first
assessed at high doses in adults, but later more sensitive
endpoints were detected at lower doses and in earlier
life-stages. One such endpoint could be vitamin K meta-
bolism and subsequent impact on blood coagulation
especially in prenatal life, and another endpoint could be
leptin metabolism and possibly body weight [47,48].
The arguments against policy actions were:
￿ The use of suggested alternative compounds [19,20]
is not proven to be safer. Less studied compounds not
subjected to risk assessment could be introduced.
￿ S i n c et h e r ei sal a c ko fk n o w l e d g er e g a r d i n gt h e
margin of exposure, the human exposure is not big
enough to cause toxic effects. The toxicological activity
appears to be lower for decaBDE compared to BDEs
with lower degrees of bromine substitution [28].
Finally there were suggestions on how to improve
knowledge on decaBDE and HBCD:
￿ Require more research and more toxicological test-
ing from the industry itself.
￿ Improve the organisation of research cooperation
between universities and research institutions at the
European level.
￿ Improve funding for the necessary research.
￿ Strengthen human cohort studies to include investi-
gations of new medications or chemicals.
￿ Require permission from an ethical committee for
production and use.
￿ Monitor the levels of decaBDE and HBCD in
h u m a n s ,f o o da n de n v i r o n m e n tt op r o v i d ei n s i g h ti n t o
the main routes of exposure and to assess the trends.
Comments on Methodology
The expert elicitation procedure can be very helpful in
quickly obtaining results as a basis for policy consideration,
when the scientific uncertainty is high. An advantage of
expert elicitation is that different experts may interpret the
available data differently, and also the diversity of opinions
among the experts is often broader than that reported in
consensus documents such as risk assessment reports [5].
All opinions will be heard even if they are raised only by
one or a few persons, such as the ethical justification for
restriction and banning of the chemicals, as opposed to
continued use of the chemicals until there is enough proof
of toxic effects. The approach is therefore well suited to
identify areas of agreement and disagreement between
experts.
The experts in our elicitation argued that the procedure
itself could have influenced the results. Individual interpre-
tations or misunderstandings of the questions in the ques-
tionnaires may have influenced the responses, and this
was considered critical. The experts also missed an
Table 3 Priority areas for decaBDE (a) and HBCD (b)
(a)
Causal box Source Envir. matrix Exposure Human body Social
Frequency 57 12 13 3
Frequency-item Frequency-group Ranking-item Ranking-total
Envir.matrix 7
Transport/transformation 4 1-1-2-2 1
Exposure 3 12 2-3-4
Ingestional 4 2-3-3-4 2
Human Body 13
Toxicokinetics 3 1-1-2 2
(b)
Causal box Source Envir. matrix Exposure Human body Social
Frequency 54 11 17 3
Frequency-item Frequency-group Ranking-item Ranking-total
Exposure 4 11 2-2-2-4 2
Human body 17
Concentration target organ 3 1-3-3 2
Toxicology 3 1-1-2 1
The table shows the frequency of the different causal boxes (elements) of the causal chain diagram in the priority listings according to their influence on the
extent of the health risk the causal diagram leads to (Upper table). The three highest ranked elements (combination of most frequently mentioned and ranking
positions), their frequency (how often the element was chosen by the experts; 5 = five experts chose it) and rank (level of priority of an element chosen by the
experts; 1 = highest) and their ranking in total (Lower table) is shown.
Ravnum et al. Environmental Health 2012, 11(Suppl 1):S7
http://www.ehjournal.net/content/11/S1/S7
Page 9 of 12optional box of “out of my expertise” or “Id o n ’tk n o w ”,
instead of only “very low confidence”, because they consid-
ered this distinction very important.
Further, experts define differently what constitutes a
policy action.This could have influenced the answers in
Questionnaire 2.
Most certainly the combination and type of experts
have affected the outcome. The loss of some answers in
the questionnaires due to technical problems with the
web-based solution could also have influenced the final
results.
We consider that the different interpretations and
misunderstandings were clarified in the workshop, and
the final advice provided in the Policy Briefs is robust.
Conclusions
The HENVINET expert elicitation procedure is an
assessment tool aimed at highlighting different view
points on knowledge-related key issues for policy mak-
ing. The procedure is not intended as a substitute for
risk assessment, but as its complement. We identified
priorities for further research on decaBDE and HBCD,
and provided valuable recommendations for policy
makers.
Priority issues for further research on decaBDE were:
studies of the magnitude of environmental transforma-
tion of decaBDE, of the extent of oral exposure in
humans, and of the fate of decaBDE in the body. Prior-
ity issues for further research on HBCD were: epidemio-
logical and toxicological studies of HBCD, more
measurements of the concentration of HBCD in the tar-
get tissues, and determination of the extent of human
exposure to HBCD.
Based on the answers to the questionnaires and the dis-
cussions at the workshop, the invited experts were not in
agreement on whether or not the current knowledge is
sufficient to justify more strict policy actions at this point.
While most experts argued that the persistence of dec-
aBDE and the transformation into bioaccumulating and
toxic compounds, and the persistence and bioaccumula-
tion properties of HBCD, are enough to justify a ban or
restrictions on use of these compounds, others believed
that more data is required before a decision to change the
status quo of these economically and technically important
compounds is justified.
Workshop participants (in alphabetical order)
Åke Bergman, Stockholm University, Sweden
Lucio G Costa, University of Washington, US
Per Ola Darnerud, National Food Administration,
Sweden
Marie Frederiksen, University of Aarhus, Denmark
Helen Håkansson, Karolinska Institutet, Stockholm,
Sweden
Janna G Koppe, Ecobaby Foundation, The Netherlands
Jan L Lyche, Norwegian School of Veterinary Science
Cathrine Thomsen, Norwegian Institute of Public
Health
Cynthia de Wit, Stockholm University, Sweden
Additional material
Additional file 1_Q1_decaBDE: Evaluation questionnaire – Causal
chain for BFR decaBDE Questionnaire 1 with explanation and
background information. Online version is available at http://henvinet.
nilu.no/EvaluationofKnowledge/tabid/1333/language/en-US/Default.aspx
Additional file 2_Q1_HBCD: Evaluation questionnaire – Causal chain
for BFR HBCD Questionnaire 1 with explanation and background
information. Online version is available at http://henvinet.nilu.no/
EvaluationofKnowledge/tabid/1333/language/en-US/Default.aspx
Additional file 3_Q2_DecaBDE: Follow-up questions on decaBDE
Questionnaire 2 on decaBDE. Experts were expected to use results of
questionnaire 1 (Additional file 3) when answering.
Additional file 4_Q2_HBCD: Follow-up questions on HBCD
Description of data: Questionnaire 2 on HBCD. Experts were expected to
use results of questionnaire 1 (Additional file 3) when answering.
Additional file 5_Policy Brief_decaBDE: HENVINET Policy Brief.
Expert Elicitation on Health Implications of decaBDE. Based on the
results from questionnaire 2 and the workshop, a policy
recommendation was written as the final product of the project.
Additional file 6_Policy Brief_HBCD: HENVINET Policy Brief. Expert
Elicitation on Health Implications of HBCD. Based on the results from
questionnaire 2 and the workshop, a policy recommendation was written
as the final product of the project.
Additional file 7_Q1 Results_decaBDE and HBCD: Additional file
3_Q1 Results Available data from questionnaire 1 of decaBDE and
HBCD. Mean, standard deviation, consensus measure and rank consensus
are presented.
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